- In a 24-patient two-part proof-of-concept study, Vertex Pharmaceuticals' (VRTX) Kalydeco (ivacaftor) demonstrated a statistically significant improvement in mean absolute lung function (percent predicted forced expiratory volume in one second (PPFEV1) after two weeks of ivacaftor treatments versus placebo (part 1) and improvements in lung function after eight weeks of treatment (part 2).
- The proof-of-concept study was the first to evaluate the use of ivacaftor in multiple residual mutations and is supported by in vitro observations that showed ivacaftor enhanced the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in cells with residual function mutations.
- Based on these data, Vertex plans to initiate a larger Phase 3 trial that will evaluate longer-term ivacaftor treatment.
Ivacaftor improves lung function in CF patients
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs